PMID- 15668276
OWN - NLM
STAT- MEDLINE
DCOM- 20050712
LR  - 20200203
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 16
IP  - 2
DP  - 2005 Feb
TI  - Serum HER2 extracellular domain in metastatic breast cancer patients treated with 
      weekly trastuzumab and paclitaxel: association with HER2 status by 
      immunohistochemistry and fluorescence in situ hybridization and with response 
      rate.
PG  - 234-9
AB  - PURPOSE: We explored the relationship between circulating HER2 extracellular 
      domain (ECD) and tissue HER2 status as determined by immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH). We also examined its predictive 
      value in a cohort of metastatic breast cancer patients treated with weekly 
      trastuzumab and paclitaxel. METHODS: Eligible patients had pre- and 
      post-treatment stored serum specimens and were treated on a previously reported 
      phase II trial. Retrospective analysis evaluated: the association between 
      pretreatment serum HER2 ECD and tissue HER2 status by IHC and FISH; and the 
      association between change in serum HER2 ECD after 12 weeks of therapy and 
      response proportion. RESULTS: Stored serum samples were available for 55/95 (58%) 
      patients. Statistically significant associations were found between HER2 status 
      as assessed by IHC and FISH, and baseline serum HER2 ECD level. Patients whose 
      ECD normalized after 12 weeks of therapy had a higher response proportion 
      compared with patients with persistently high ECD levels (68% versus 15%, 
      P=0.005). A relative decline of over 55% from baseline HER2 ECD predicted 
      response to therapy. CONCLUSION: A statistically significant association was 
      observed between pretreatment serum HER2 ECD and tissue HER2 status as assessed 
      by IHC and FISH. A decrease in serum HER2 ECD level was a significant predictor 
      of response to trastuzumab-based therapy.
FAU - Fornier, M N
AU  - Fornier MN
AD  - Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of 
      Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 
      10021, USA. fornierm@mskcc.org
FAU - Seidman, A D
AU  - Seidman AD
FAU - Schwartz, M K
AU  - Schwartz MK
FAU - Ghani, F
AU  - Ghani F
FAU - Thiel, R
AU  - Thiel R
FAU - Norton, L
AU  - Norton L
FAU - Hudis, C
AU  - Hudis C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*drug therapy/*genetics/pathology
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - *Neoplasm Metastasis
MH  - Paclitaxel/administration & dosage
MH  - Receptor, ErbB-2/*blood
MH  - Retrospective Studies
MH  - Tissue Distribution
MH  - Trastuzumab
EDAT- 2005/01/26 09:00
MHDA- 2005/07/13 09:00
CRDT- 2005/01/26 09:00
PHST- 2005/01/26 09:00 [pubmed]
PHST- 2005/07/13 09:00 [medline]
PHST- 2005/01/26 09:00 [entrez]
AID - S0923-7534(19)48416-0 [pii]
AID - 10.1093/annonc/mdi059 [doi]
PST - ppublish
SO  - Ann Oncol. 2005 Feb;16(2):234-9. doi: 10.1093/annonc/mdi059.